# DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

> **NCT07288112** · PHASE1,PHASE2 · RECRUITING · sponsor: **Diakonos Oncology Corporation** · enrollment: 35 (estimated)

## Conditions studied

- Refractory Melanoma

## Interventions

- **BIOLOGICAL:** DOC1021
- **PROCEDURE:** Tumor resection
- **DRUG:** pIFN (peginterferon alfa-2a)

## Key facts

- **NCT ID:** NCT07288112
- **Lead sponsor:** Diakonos Oncology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2031-01
- **Final completion:** 2033-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288112, "DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07288112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*